Skip to main content
SpringerLink
Log in
Book cover

Atlas of Diabetes pp 375–417Cite as

Newer Diabetes Medications

  • Chapter
  • First Online:

  • 3682 Accesses

Abstract

Before 1995, the only approved medications in the USA for the treatment of diabetes hyperglycemia were various insulin preparations and a number of sulfonylureas. Previously, the Food and Drug Administration (FDA) removed the biguanide phenformin from the market in 1977 due to its potential to induce fatal lactic acidosis. However, although almost every other country in the world was marketing metformin (which made its initial appearance in the 1950s), the patent for the drug had long since expired, leaving companies with little motivation to go through the registration process to bring metformin to the US market due to the immense possibility of generic copying.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132:2131–2157.

    Article  PubMed  CAS  Google Scholar 

  2. Nauck MA, Homberger E, Siegel EG, et al.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492–498.

    Article  PubMed  CAS  Google Scholar 

  3. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46–52.

    Article  PubMed  CAS  Google Scholar 

  4. Toft-Nielsen MB, Damholt MB, Madsbad S, et al.: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717–3723.

    Article  PubMed  CAS  Google Scholar 

  5. DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092–1100.

    Article  PubMed  CAS  Google Scholar 

  6. Buse JB, Henry RR, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628–2635.

    Article  PubMed  CAS  Google Scholar 

  7. Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083–1091.

    Article  PubMed  CAS  Google Scholar 

  8. Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Int Med 2005, 143:559–569.

    PubMed  CAS  Google Scholar 

  9. Bunck MC, Diamant M, Cornér A, et al.: One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762–768.

    Article  PubMed  CAS  Google Scholar 

  10. Nauck MA, Duran S, Kim D, et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259–267.

    Article  PubMed  CAS  Google Scholar 

  11. Gallwitz B, Böhmer M, Segiet T, et al.: Exenatide vs. insulin aspart in patients with type 2 diabetes: results of a randomised, open-label study. Diabetologia 2010, 53(Suppl 2): 862.

    Google Scholar 

  12. Riddle M, Ahmann A, Basu A, et al.: Metformin  +  exenatide  +  basal insulin vs metformin  +  placebo  +  basal insulin: reaching A1c <6.5% without weight-gain or serious hypoglycemia. American Diabetes Association Annual Scientific Sessions 2010, late-breaking abstract, poster 18-LB.

    Google Scholar 

  13. Buse JB, Bergenstal RM, Glass LC, et al.: Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes. Ann Intern Med 2011, 154:103–112.

    PubMed  Google Scholar 

  14. Garber A, Henry R, Gracia-Hernandez PA, et al.: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473–481.

    Article  PubMed  CAS  Google Scholar 

  15. Nauck M, Frid A, Hermansen K, et al.: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. The LEAD-2 Study. Diabetes Care 2009, 32:84–90.

    Google Scholar 

  16. Marre M, Shaw J, Brandle M, et al.: Liraglutide, a once-daily human analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268–278.

    Article  PubMed  CAS  Google Scholar 

  17. Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met  +  TZD). Diabetes Care 2009, 32:1224–1230.

    Article  PubMed  CAS  Google Scholar 

  18. Russell-Jones D, Vaag A, Schmitz O, et al.: Liraglutide versus insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met  +  SU): a randomized controlled trial. Diabetologia 2009, 52:2046–2055.

    Article  PubMed  CAS  Google Scholar 

  19. Buse JB, Rosenstock J, Sesti G, et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39–47.

    Article  PubMed  CAS  Google Scholar 

  20. Pratley RE, Nauck M, Bailey T, et al.: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447–1456.

    Article  PubMed  CAS  Google Scholar 

  21. Drucker DJ, Buse JB, Taylor K, et al.: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240–1250.

    Article  PubMed  CAS  Google Scholar 

  22. Buse JB, Drucker DJ, Taylor KL, et al.: DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 33:1255–1261.

    Article  PubMed  CAS  Google Scholar 

  23. Bergenstal RM, Wysham C, MacConell L, et al.: Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431–439.

    Article  PubMed  Google Scholar 

  24. Diamant M, Van Gaal L, Stranks S, et al.: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234–2243.

    Article  PubMed  CAS  Google Scholar 

  25. Nauck MA, Ratner RE, Kapitza C, et al.: Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009, 32:1237–1243.

    Article  PubMed  CAS  Google Scholar 

  26. Gerich JE, Fonseca VA, Alvarado-Ruiz R, et al.: Monotherapy with GLP-1 receptor agonist, Lixisenatide, significantly improves glycaemic control in type 2 diabetic patients. Diabetologia 2010, 53(Suppl 2):abstract 830.

    Google Scholar 

  27. Rosenstock J, Reusch J, Bush M, et al.: Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880–1886.

    Article  PubMed  CAS  Google Scholar 

  28. Umpierrez G, Blevins T, Rosenstock J, et al.: The effect of LY2189265 (GLP-1 analogue) once weekly on HbA1c and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis. Diabetologia 2009, 52(Suppl 1):abstract OP-22.

    Google Scholar 

  29. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929–2940.

    Article  PubMed  CAS  Google Scholar 

  30. Deacon CF: Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7–18.

    Article  PubMed  CAS  Google Scholar 

  31. Herman GA, Bergman A, Stevens C, et al.: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612–4619.

    Article  PubMed  CAS  Google Scholar 

  32. Mari A, Sallas WM, He YL, et al.: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90:4888–4894.

    Article  PubMed  CAS  Google Scholar 

  33. Brazdg R, Xu L, Dalla Man C, et al.: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:186–193.

    Google Scholar 

  34. Aschner P, Kipnes MS, Lunceford JK, et al.: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632–2637.

    Article  PubMed  CAS  Google Scholar 

  35. Charbonnel B, Karasik A, Liu J, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638–2643.

    Article  PubMed  CAS  Google Scholar 

  36. Rosenstock J, Brazg R, Andryuk PJ, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556–1568.

    Article  PubMed  CAS  Google Scholar 

  37. Nauck MA, Meininger G, Sheng D, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194–205.

    Article  PubMed  CAS  Google Scholar 

  38. Goldstein BJ, Feinglos MN, Lunceford JK, et al.: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979–1987.

    Article  PubMed  CAS  Google Scholar 

  39. Schweizer A, Couturier A, Foley JE, Dejager S: Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007, 24:955–961.

    Article  PubMed  CAS  Google Scholar 

  40. Ahrén B, Gomis R, Standl E, et al.: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874–2880.

    Article  PubMed  Google Scholar 

  41. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al.: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611–622.

    Article  PubMed  CAS  Google Scholar 

  42. Chacra AR, Tan GH, Apanovitch A, et al.: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009, 63:1395–1406.

    Article  PubMed  CAS  Google Scholar 

  43. Hollander P: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, 94:4810–4819.

    Article  PubMed  CAS  Google Scholar 

  44. Rosenstock J, Rendell MS, Gross JL, et al.: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009, 11:1145–1152.

    Article  PubMed  CAS  Google Scholar 

  45. Pratley RE, Reusch JE, Fleck PR, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009, 25:2361–2371.

    Article  PubMed  CAS  Google Scholar 

  46. Pratley RE, Kipnes MS, Fleck PR, et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009, 11:167–176.

    Article  PubMed  CAS  Google Scholar 

  47. Nauck MA, Ellis GC, Fleck PR, et al.: Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63:46–55.

    Article  PubMed  CAS  Google Scholar 

  48. Rosenstock J, Inzucchi SE, Seufert J, et al.: Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010, 33:2406–2408.

    Article  PubMed  CAS  Google Scholar 

  49. Del Prato S, Barnett AH, Huisman H, et al.: Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial. Diabetes Obes Metab 2011, 13:[Epub ahead of print] 3 Dec 2010.

    Google Scholar 

  50. Taskinen MR, Rosenstock J, Tamminen I, et al.: Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:65–74.

    Article  PubMed  CAS  Google Scholar 

  51. Owens DR, Swallow R, Jones P, et al.: Linagliptin improves glycemic control in type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain or hypoglycemia. Diabetes 2010, 59(Suppl 1):abstract 548-P.

    Google Scholar 

  52. Gomis R, Espadero RM, Jones R, et al.: Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes. Diabetes 2010, 59(Suppl 1):abstract 551-P.

    Google Scholar 

  53. Meier AH, Cincotta A: Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996, 4:464–487.

    Google Scholar 

  54. Scranton RE, Farwell W, Ezrokhi M, et al.: Quick release bromocriptine (Cycloset™) improves glycaemic control in patients with diabetes failing metformin/sulfonylurea combination therapy. Diabetologia 2008, 51(Suppl 1):abstract 930.

    Google Scholar 

  55. Cincotta AH, Gaziano JM, Ezrokhi M, Scranton R: Cycloset (quick-release bromocriptine mesylate), a novel centrally acting treatment for type 2 diabetes. Diabetologia 2008, 51(Suppl 1):abstract 39.

    Google Scholar 

  56. Gaziano JM, Cincotta AH, O’Connor CM, et al.: Randomized clinical trial of quick release-bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010, 33:1503–1508.

    Article  PubMed  CAS  Google Scholar 

  57. Fonseca VA, Handelsman Y, Staels B: Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 2010, 12:384–392.

    Article  PubMed  CAS  Google Scholar 

  58. Unger RH, Foster DW: Diabetes mellitus. In Williams Textbook of Endocrinology, edn. 8. Edited by Wilson JD and Foster DW. Philadelphia: WB Saunders; 1992:1273–1275.

    Google Scholar 

  59. Kruger DF, Gatcomb PM, Owen SK: Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999, 25:389–397.

    Article  PubMed  CAS  Google Scholar 

  60. Weyer C, Gottlieb A, Kim DD, et al.: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes. Diabetes Care 2003, 26:3074–3079.

    Article  PubMed  CAS  Google Scholar 

  61. Edelman SV, Darsow T, Frias JP: Pramlintide in the treatment of diabetes. Int J Clin Pract 2006, 60:1647–1653.

    Article  PubMed  CAS  Google Scholar 

  62. Edelman S, Garg S, Frias J, et al.: A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006, 29:2189–2195.

    Article  PubMed  CAS  Google Scholar 

  63. Riddle M, Pencek R, Charenkavanich S, et al.: Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009, 32:1577–1582.

    Article  PubMed  CAS  Google Scholar 

  64. Heinemann L, Heise T: Current status of the development of inhaled insulin. Br J Diabetes Vasc Dis 2004, 4:295–301.

    Article  CAS  Google Scholar 

  65. Potocka E, Cassidy JP, Haworth P, et al.: Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol 2010, 4:1164–1173.

    PubMed  Google Scholar 

  66. Rosenstock J, Lorber DL, Gnudi L, et al.: Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010, 375:2244–2253.

    Article  PubMed  CAS  Google Scholar 

  67. Bailey CJ: Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011, 32:[Epub ahead of print] 4 Jan 2011.

    Google Scholar 

  68. Wilding JP, Norwood P, T’joen C, et al.: A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656–1662.

    Article  PubMed  CAS  Google Scholar 

  69. Bailey CJ, Gross JL, Pieters A, et al.: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223–2233.

    Article  PubMed  CAS  Google Scholar 

  70. Rosenstock J, Arbit D, Usiskin K, et al.: Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Diabetes 2010, 59(Suppl 1):abstract 77-OR.

    Google Scholar 

  71. Ferrannini E, Seman LJ, Seewaldt-Becker E, et al. The potent and highly selective sodium-glucose co-cransporter (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2010, 53(Suppl 2):abstract 877.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research & Academic Programs, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA

    Jay S. Skyler MD, MACP (Professor of Medicine, Pediatrics, and Psychology, Deputy Director)

Authors
  1. Jay S. Skyler MD, MACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jay S. Skyler MD, MACP .

Editor information

Editors and Affiliations

  1. Division of Endocrinology,, Diabetes & Metabolism, University of Miami, Miami, 33136, Florida, USA

    Jay Skyler

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Skyler, J.S. (2012). Newer Diabetes Medications. In: Skyler, J. (eds) Atlas of Diabetes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1028-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1028-7_18

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-1027-0

  • Online ISBN: 978-1-4614-1028-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation